Pediatric high-grade gliomas and the WHO CNS Tumor Classification—Perspectives of pediatric neuro-oncologists and neuropathologists in light of recent updates. Issue 1 (20th May 2022)

• Record Type: Journal Article
• Authors: Gielen, Gerrit H; Baugh, Joshua N; van Vuurden, Dannis G; Veldhuijzen van Zanten, Sophie E M; Hargrave, Darren; Massimino, Maura; Biassoni, Veronica; Morales la Madrid, Andres; Karremann, Michael; Wiese, Maria; Thomale, Ulrich; Janssens, Geert O; von Bueren, André O; Perwein, Thomas; Nussbaumer, Gunther; Hoving, Eelco W; Niehusmann, Pitt; Gessi, Marco; Kwiecien, Robert; Bailey, Simon; Pietsch, Torsten; Andreiuolo, Felipe; Kramm, Christof M
• Is Part Of: Neuro-oncology advances. Volume 4:Issue 1(2022)
• Publication Date: 2022-05-20
• Subjects: diffuse midline glioma -- DIPG -- pediatric high-grade glioma -- World Health Organization; 616.99481
• DOI: 10.1093/noajnl/vdac077
• Languages: English
• ISSNs: 2632-2498

Abstract

Abstract: Background: The WHO Classification of Tumors of the Central Nervous System has undergone major restructuring. Molecularly defined diagnostic criteria were introduced in 2016 (revised 4th edition) and expanded in 2021 (5th edition) to incorporate further essential diagnostic molecular parameters. We investigated potential differences between specialists in perception of these molecularly defined subtypes for pediatric high-grade gliomas (pedHGG). Methods: We designed a 22-question survey studying the impact of the revised 4th edition of the WHO classification on pedHGG. Data were collected and statistically analyzed to examine the spectrum of viewpoints and possible differences between neuro-oncologists and neuropathologists. Results: 465 participants from 53 countries were included; 187 pediatric neuro-oncologists (40%), 160 neuropathologists (34%), and 118 additional experts (26%). Neuro-oncologists reported issues with the introduction of molecularly defined tumor types, as well as the abolishment or renaming of established tumor entities, while neuropathologists did not to the same extent. Both groups indicated less relevant or insufficient diagnostic definitions were available in 2016. Reported issues were classified and assessed in the 2021 WHO classification and a substantial improvement was perceived. However, issues of high clinical relevance remain to be addressed, including the definition of clinical phenotypes for diffuse intrinsic pontine glioma and gliomatosis cerebri. Conclusions: Within the WHO classification of pediatric brain tumors, such as pedHGG, rapid changes in molecular characterization have been introduced. This study highlights the ongoing need for cross talk between pathologist and oncologist to advance the classification of pedHGG subtypes and ensure biological relevance and clinical impact.